References
- Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710–717.
- Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–328.
- El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32(6):720–737.
- Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American gastroenterological association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1383–1391.
- Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of barrett’s esophagus. Am J Gastroenterol. 2010;105(8):1729.
- Spechler SJ, Sharma P, Souza RF, et al. American gastroenteological association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140(3):1084–1091.
- Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129(6):1825–1831.
- Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology. 2002;123(2):461–467.
- Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125(6):1670–1677.
- Thrift AP, Kendall BJ, Pandeya N, et al. A clinical risk prediction model for Barrett esophagus. Cancer Prev Res. 2012;5(9):1115–1123.
- Thrift AP, Garcia JM, El-Serag HB. A multibiomarker risk score helps predict risk for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2014;12(8):1267–1271.
- Dellon ES, Jensen ET, Martin CF, et al. Prevalence of eosinophilic esophagitis in the United States. Clin Gastroenterol Hepatol. 2014;12:589.
- Roman S, Kahrilas PJ. Mechanisms of Barrett’s oesophagus (clinical): LOS dysfunction, hiatal hernia, peristaltic defects. Best Pract Res Clin Gastroenterol. 2015;29(1):17–28.
- Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172–180.
- Furuta GT, Katzka DA. Eosinophilic esophagitis. N Engl J Med. 2015;373:1640–1648.
- Richter JE. IM and the squamocolumnar junction: what does it all mean? Gut. 1998;42:604–605.
- Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and norman barrett. Gastroenterology. 1996;110:614–621.
- Sharma P, Morales TG, Sampliner RE. Short segment Barrett’s esophagus – the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol. 1998;93:1033–1036.
- Chalasani N, Wo JM, Hunter JG, et al. Significance of intestinal metaplasia in different areas of esophagus including esophagogastric junction. Dig Dis Sci. 1997;42:603–607.
- Rubenstein JH, Morgenstern H, Appelman H, et al. Prediction of Barrett’s esophagus among men. Am J Gastroenterol. 2013;108(3):353–362.
- Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108:679–692.
- Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut. 2013;62(6):824–832.